The Cannabis Company That Won't Mix Work With Pleasure
A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully.
For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users.
“If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said.
Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market.
“It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.”
And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021.
For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).
Chiza Vitta, Managing Director Global Analytics at S&P Global Ratings joined Cheddar to discuss S&P's recent Megatrend findings and other 2025 predictions.
Greg O'Hara CEO at Certares joined Cheddar to discuss his personal experience with Wellness Tourism and his predictions for the future of the growing industry.
Meghna Maharishi, Airlines Reporter at Skift, answers your biggest questions about what is happening since Spirit Airlines filed for bankruptcy. Watch!
Managing Director at Wells Fargo, Adam Davis, joins Cheddar to discuss how both the consumer and retailer are approaching shopping's busiest time of the year.
